Eli Lilly announced a $4.5 billion investment to expand its manufacturing facilities in Lebanon, Indiana, bringing its total capital commitments in the state to over $21 billion since 2020. This includes opening Lilly Lebanon Advanced Therapies, the company's first dedicated genetic medicine manufacturing plant, designed for clinical and commercial production of advanced genetic therapies. The expansion supports production of key medicines like Zepbound, Mounjaro, Foundayo, and investigational drug retatrutide, reflecting Lilly's focus on innovative treatments for obesity, diabetes, and cardiometabolic diseases. The Lebanon site is set to become the largest active pharmaceutical ingredient production facility in U.S. history by 2027, reinforcing Indiana's role in life sciences and advanced manufacturing.
